How do biopharma companies turn scientific innovation into meaningful reach for patients when capital and capabilities are finite?
At the 2026 LSX Congress USA in Boston, Blue Matter Managing Partner Pankaj Oza moderated two panels that tackled this question from different angles: expanding into new global markets and commercializing therapies for rare diseases. In this white paper, Pankaj Oza and Emily Borrello distill the key insights from senior leaders at emerging and established companies across the US, Europe, and Asia. Topics include how to give each geography a defined role in the value chain, when to build versus partner, how to assess the reachable rather than theoretical patient population, and why commercial strategy should start early while investment scales with evidence. Whether you attended the sessions or are weighing similar decisions for your own organization, download the full paper for practical lessons on focusing resources, partnering with purpose, and keeping patient reach at the center of strategy.
